Scientia CME Immunology – Allergy CME has three selections:
• Chronic Urticaria (CU): Therapeutic Updates, Best Practices, and Barriers to Care (1 hr CME);
• Psoriasis: Best Practices, Barriers to Care, and Emerging Therapies (1 hr CME)
• Asthma and allergic asthma: personalizing treatment to the patient and therapeutic updates (1 hr CME)

Target Audience:
Physicians specializing in Allergy or Dermatology.

Scientia CME Critical Care contains about 70 courses dealing with many aspects of critical care.

Courses are organized into these sections:
• Scientia CME Critical Care – ERAS (Enhanced Recovery After Surgery)
• Scientia CME Critical Care – Glucose Management
• Scientia CME Critical Care – Goal Directed Therapy
• Scientia CME Critical Care – Hemodynamics
• Scientia CME Critical Care – Pharmacotherapy Literature Updates
• Scientia CME Critical Care – Sepsis

Target Audience:
Physicians focusing on Critical Care, Hospital Medicine, or Emergency Medicine.

In Current Treatment Options for C. difficile Infection and the Emergence of Hypervirulent Strains, a leading clinician discusses the increasing incidence and resistance of C. difficile, as well as hypervirulent strains, and evaluates current therapeutic agents for CDI in terms of safety, efficacy, and improvement of patient outcomes.

Upon successful completion of Current Treatment Options for C. difficile Infection and the Emergence of Hypervirulent Strains, you should be better able to:
• Assess the increasing incidence of C. difficile infection, as well as hypervirulent strains, in and outside of the hospital setting.
• Differentiate current treatment options for C. difficile infection in terms of safety, efficacy, and improvement of patient outcomes.

Target Audience: Gastroenterologists, infectious disease specialists, and other health care professionals involved in the treatment of patients with Clostridium difficile (C. difficile) infections.

In Guidelines and Strategies to Reduce C. difficile Infection Recurrence, a leading clinician discusses evidence-based guidelines for the management of Clostridium difficile infections (CDI) and evaluates therapeutic agents under investigation that may aid in treatment and reduce the occurrence of CDI.

Upon successful completion of Guidelines and Strategies to Reduce C. difficile Infection Recurrence, you should be better able to:
• Apply current evidence-based guidelines for the overall management of C. difficile infection.
• Incorporate treatment strategies that may reduce C. difficile infection recurrence, as well as antibiotic resistance.

Target Audience:
Gastroenterologists, infectious disease specialists, and other health care professionals involved in the treatment of patients with Clostridium difficile (C. difficile) infections.

Advances in Treating Metastatic Colorectal Cancer (CRC) discusses the diagnosis and treatment of metastatic colorectal cancer (mCRC).

By the end of Advances in Treating Metastatic Colorectal Cancer (CRC), you will be better able to:
• Describe present the current practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
• Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
• Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
• Describe the challenges and barriers to care associated with treating patients with mCRC

In order to receive credit from ScientiaCME, you must first establish a username and password.

Target Audience:
Medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

Carcinoid Syndrome: Updates in Pathophysiology, Diagnosis, and Treatment consists of a single lecture and discussion by Drs. Matthew H. Kulke and C. Metz.

After viewing Carcinoid Syndrome, you will be better able to:
• Summarize the cause of carcinoid syndrome
• Perform an appropriate workup and differential diagnosis from presenting symptoms
• Adopt evidence-based best practices in managing carcinoid syndrome, including strategies to address refractory or poorly controlled symptoms
• Evaluate safety and efficacy of current and emerging treatment approaches for carcinoid syndrome

Target Audiences:
This program is intended for US-based medical oncologists, endocrinologists and gastroenterologists, as well as oncology physician assistants, nurse practitioners, and nurses involved in the diagnosis and management of carcinoid tumors and carcinoid syndrome.

Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are Crohn’s Disease and ulcerative colitis, the former of which affects any area of the alimentary canal.

After reviewing Crohn’s Disease: Therapeutic Updates, Barriers to Care, and Emerging Therapies, you will be better able to:
• Describe the strengths and weaknesses of present and emerging diagnostic techniques, where applicable in Crohn’s disease.
• Describe strengths of different professional organizations’ guidance in Crohn’s disease diagnosis and treatment guidelines
• Describe emerging therapies in the treatment of Crohn’s disease.
• Describe barriers to care in the treatment of Crohn’s disease and suggest ways to ameliorate them.
• Identify the present treatment options currently available for management of Crohn’s disease and apply them to patient cases using evidence-based medicine.

Target Audience:
Healthcare professionals specializing in: gastroenterology, internal medicine, or those who otherwise commonly care for patients with Crohn’s disease.

This course contains two courses:
• Crohn’s Disease: Therapeutic Updates, Barriers to Care, and Emerging Therapies (1 hr CME)
• Inflammatory Bowel Disease (IBD): A Global Approach to Quality Management and Barriers to Care in an Era of Resource Consciousness(1.25 hr CME)

In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audience:
Healthcare professionals specializing in colon and rectal surgery, family medicine, internal medicine, gastroenterology, oncology, pain management, palliative care, primary care, proctology, and other clinicians who treat patients suffering from gastrointestinal disorders.

The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
• Recall updates in the staging, prognosis, and diagnosis of MM.
• Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
• Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
• Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

Target Audience:
Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

ScientiaCME Hematology/Oncology has eight lectures for MDs:
• Acute Lymphoblastic Leukemia (ALL): Highlights from the ASH 2016: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation (0.5 hr CME)
• Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society for Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation (0.75 hr CE)
• Advancing Treatment Strategies in Acute Lymphoblastic Leukemia (ALL) Drug Therapy
• Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options (1 hr CE)
• Acute Lymphoblastic Leukemia (ALL): Highlights from the ASH 2015: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation (1 hr CME)
• The Newest in Non-Small Cell Lung Cancer (NSCLC): Emerging Therapies, Novel Approaches, Therapeutic Updates, and Barriers to Care and Incorporating Best Practice (1 hr CME)
• Renal cell carcinoma (RCC): Highlights from the 2015 American Society of Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation (1 hr CME)
• Acute Lymphoblastic Leukemia in Adults (1 hr CME)

In order to get credit from ScientiaCME, you must first establish a username and password.

Target Audience: Hematologists